skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Mostrar Somente
Refinado por: Nome da Publicação: Bmc Cancer remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial

Borgers, J S W ; Burgers, F H ; Terveer, E M ; van Leerdam, M E ; Korse, C M ; Kessels, R ; Flohil, C C ; Blank, C U ; Schumacher, T N ; van Dijk, M ; Henderickx, J G E ; Keller, J J ; Verspaget, H W ; Kuijper, E J ; Haanen, J B A G

BMC cancer, 2022-12, Vol.22 (1), p.1366-11, Article 1366 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
2
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
Material Type:
Artigo 		Adicionar ao Meu Espaço

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

De Groot, S ; Sleijfer, S ; Redekop, W K ; Oosterwijk, E ; Haanen, J B A G ; Kiemeney, L A L M ; Uyl-de Groot, C A

BMC cancer, 2016-06, Vol.16 (1), p.364-364, Article 364 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
3
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

Mulder, E E A P ; de Joode, K ; Litière, S ; Ten Tije, A J ; Suijkerbuijk, K P M ; Boers-Sonderen, M J ; Hospers, G A P ; de Groot, J W B ; van den Eertwegh, A J M ; Aarts, M J B ; Piersma, D ; van Rijn, R S ; Kapiteijn, E ; Vreugdenhil, G ; van den Berkmortel, F W P J ; Hoop, E Oomen-de ; Franken, M G ; Ryll, B ; Rutkowski, P ; Sleijfer, S ; Haanen, J B A G ; van der Veldt, A A M

BMC cancer, 2021-03, Vol.21 (1), p.323-323, Article 323 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
4
Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
Material Type:
Artigo 		Adicionar ao Meu Espaço

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

Lindenberg, M. ; Retel, V. ; Rohaan, M. ; Berg, J. van den ; Haanen, J. ; Harten, W. van

BMC Cancer, 2020-07, Vol.20

BMC

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.